12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cinryze regulatory update

FDA approved an sBLA from ViroPharma for industrial scale manufacturing changes for hereditary angioedema (HAE) drug Cinryze. In February, ViroPharma received a complete response letter for...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >